Therakind United Kingdom

Therakind, a, private pharmaceutical company, is focused on developing safe, effective, authorised speciality medicines. To date, two paediatric products have been successfully developed and commercialised and a portfolio of further products are under development in late stage development Therakind is developing a portfolio of further products. We have an earlier stage diabetic nasal product for treatment of hypoglycaemia and a pipeline of further products.

Therakind operates with several business models to generate a platform of products generating royalties and also provides consultancy in pharmaceutical development.

Organisation type
Dr Susan Conroy
LinkedIn logo CEO 

Touchlight Genetics United Kingdom

Touchlight’s in vitro enzymatic DNA amplification platform addresses every major limitation of pDNA fermentation. Touchlight’s platform has improved yield, speed & fidelity, no antibiotic resistance & the ability to amplify complex secondary structures.

Organisation type
Dr Tommy Duncan
LinkedIn logo Group Business Development Officer 
Miss Sarah Milsom
Group Business Development Manager 

Ubiquigent United Kingdom

Ubiquigent provides its partners with unparalleled access to the technologies, skills and expertise required to support drug discovery in the ubiquitin field. The ubiquitin system offers many new drug discovery target opportunities across multiple therapeutic areas including cancer, cardiovascular and metabolic, neurological and musculoskeletal, and infection and immunity.

To support the exploitation of the ubiquitin system Ubiquigent has recently launched the first novel compound library designed to target Deubiquitylase (DUB) enzymes (DUBtarget-001), with further compound libraries to follow. Ubiquigent also provides access to specialist drug discovery services, high quality research tools and chemistry to support groups that are either already active in or wish to enter this exciting new field.

The ubiquitin system is based on the modification of proteins through the attachment of the protein ubiquitin, or ubiquitin-like proteins (Ubls). Ubiquitylation and related Ubl modifications are key to the control of cellular protein homeostasis as well as signalling, akin to the critical role played by phosphorylation (approximately 30% of commercial drug discovery programmes target phosphorylation enzymes), and holds similar if not greater potential for clinical utility.

Ubiquigent’s scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery. Ubiquigent benefits from high calibre backing including from IP Group plc, US investors, the UK Medical Research Council, and the University of Dundee. The company’s headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen). In addition to Ubiquigent’s own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers on site), technological competencies, and assay and analytical platforms.

Organisation type
Mr Jason Mundin
Commercial Director 
Dr Jason Brown
Scientific Director